3P Innovation Launches Generic Next-Gen DPI Filling Technology
The new DPI filling technology is an enhanced equivalent to the original filling system for the GSK Diskus DPI and will be available to manufacturers looking to produce generic products from the original Diskus and Ellipta products.
International automation company that specializes in high-precision liquid and powder drug filling systems, 3P innovation, has launched a next-generation dry powder inhaler (DPI) filling technology. The product launch was announced by the company in an April 30, 2025 press release (1).
The next-gen technology is an enhanced equivalent to the company’s original high-speed powder filling system for the GSK Diskus DPI, the patent for which has expired. According to the company, the new DPI filling technology has the ability to fill inhalers with dry powder up to five times faster than alternative technologies. Additionally, the product is able to handle more challenging, highly potent, and dusty powders with greater containment. Furthermore, the new technology will be able to process magnesium stearate and powders containing lubricants, which will enable the production of novel DPI formulations that include combining APIs.
“Therapeutic developers are shifting their focus toward more efficient drug delivery methods. Inhalable therapies are gaining significant attention because they offer rapid onset of action and bypass the harsh conditions of the gastrointestinal tract. As a result, they can enhance treatment effectiveness and lower dosage needs,” said Tom Bailey, Founder of 3P innovation, and the leading developer responsible for the patenting of the high-speed powder filling system for the GSK Diskus DPI, which later became integral to the GSK Ellipta inhaler, in the company press release (1). “Demand for these inhalable products is also growing, driven by the increasing incidence of respiratory diseases. Coupled with advancements in biologic therapies, this trend is expected to lead to a rise in the number of treatments administered via inhalation in the coming years.”
The new product will be available for drug manufacturers, seeking to produce generic versions of the original Diskus and Ellipta products, and 3P innovation will build bespoke filling systems that meet specific requirements of developers, pharmaceutical firms, or contract manufacturers.
“The expiry of the Diskus DPI patent will enable lower cost medications and an improved access to an increased number of therapeutic options,” added Bailey in the press release (1). 3P innovation has now created an equivalent high-speed powder filling system which is far more cost-effective and faster than market alternatives. This represents a considerable commercial and growth opportunity for 3P innovation. This will also have considerable benefits for patients of respiratory conditions as well as for healthcare systems internationally.”
As the generic versions of Diskus and Ellipta are expected to launch in 2029, 3P innovation will be installing commercial lines of its new product over the course of the next 12 months.
According to market research, the DPI market is forecast to experience growth at a compound annual rate of 3.6% from 2026 to 2032 (2). Growth factors for the market include the increasing prevalence of chronic respiratory diseases, growing tendency for patients to self-medicate, and technological developments in DPIs.
References
3P innovation. 3P Innovation Launches Next-Gen DPI Filling Technology for Novel Inhalation Therapeutics. Press Release, April 30, 2025.
Verified Market Research. Dry Powder Inhaler (DPI) Market Size by Product Type (Capsule-based, Blister-based, Reservoir/Cartridge-based), by Application (Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Asthma), by Sales Channel (Offline, Online) and Region for 2026–2032. Market Research Report, April 2025.